Altria Group is rated Sell because its stock trades at a 30% premium to its historical price-to-earnings ratio, despite stagnant financial results and uncertain growth prospects in smoke-free products. While its Q1 performance in traditional smokeable tobacco outperformed the industry, its oral tobacco segment, including the on! brand, faces challenges with growing shipments but losing market share amid intense competition. Management reaffirmed its 2026 earnings per share guidance but remains cautious due to macroeconomic uncertainties and doubts about near-term margin growth. Although Altria's strong gross margins and cash flow support dividends, the long-term decline in cigarette consumption and unclear outlook for oral tobacco limit its investment appeal.
The Dividend Harvesting Portfolio surpassed $40,000 in value, achieving a 43.6% return on invested capital by focusing on consistent dividend income growth rather than market timing. Its forward annualized dividend income reached $3,158.42 with a 7.8...
The NEOS S&P 500 High Income ETF (SPYI) has returned 8% year-to-date and 19% over the past year, driven mainly by its 12% annualized distribution from selling call options on S&P 500 stocks. However, with market volatility (VIX) decreasing below its ...
